Po‐Lan Su

Po-Lan Su's research centers on lung cancer, particularly EGFR- and ALK-mutated non-small cell lung cancer, examining treatment outcomes, drug safety (including cardiovascular risks), resistance mechanisms, and real-world effectiveness of targeted therapies and immunotherapies. The work also spans broader clinical topics such as lung injury treatments, machine learning for cancer outcome prediction, and other oncology and pulmonary conditions, often through retrospective and real-world cohort studies. This research would suit students interested in clinical oncology, pharmacoepidemiology, and translational approaches to lung cancer care.

Publication output has grown substantially over the past decade, rising from a handful of papers per year in 2017-2018 to a peak of 20 in 2025, though with some year-to-year fluctuation.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026